Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Viagra for the brain? new trial tests sildenafil in chronic TBI patients

NCT ID NCT05782244

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether sildenafil citrate (the drug in Viagra) can improve blood vessel function in the brain of people who had a traumatic brain injury (TBI) at least 6 months ago. Researchers will give different doses (20, 40, or 80 mg) or a placebo to 160 adults aged 18-70. The main goal is to find the best dose for improving brain blood flow, while also checking safety and whether it helps with long-term symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sildenafil citrate (Viagra)
What this could lead to
If successful, this could point toward a treatment to improve brain blood vessel function and potentially reduce long-term symptoms after traumatic brain injury.
What could go wrong
This is an early Phase 2 trial with only 160 participants, so results may not apply to everyone. Sildenafil can cause side effects like headache, flushing, and low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria To be eligible to participate in this study, an individual must meet all of the following criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged 18-70 4. Defense Enrollment Eligibility Reporting System (DEERS) eligible (WRNMMC only; N/A for UPenn) 5. History of TBI greater than 6 months and less than 25 years prior to enrollment, based on the 2023 American Congress of Rehabilitation Medicine Criteria92; 1. Plausible Mechanism of Injury: Criterion 1 focuses on the external force that likely disrupted brain function, including blast/explosion forces and acknowledging intentional causes. 2. Clinical Signs: Criterion 2 highlights signs observed or elicited during examination, distinguishing them from subjective symptoms. 3. Acute Symptoms: Criterion 3 considers subjective acute symptoms, requiring at least two symptoms to be present. 4. Clinical Examination/Laboratory Findings: Criterion 4 is a new addition, incorporating findings like cognitive impairment or oculomotor impairment. 5. Neuroimaging: While not required for diagnosis, neuroimaging can be used to provide further evidence of brain injury. 6. Chronic persistent post-concussive symptoms (Symptom Score \> 1 on at least 3 items from the Rivermead Post-Concussion Symptom Questionnaire; RPQ) 7. Glasgow Outcome Scale-Extended (GOSE) between 5-7 8. Ability to take oral medication and be willing to adhere to the study intervention regimen 9. Ability to participate in and complete 1 MRI including 2 CVR challenges and 4-week treatment period. 10. Adequate hearing and vision based on self-report and examiner's observation Exclusion Criteria An individual who meets any of the following criteria will be excluded from participation in this study: 1. Contraindication to sildenafil which includes the following: 1. Current/ongoing (within past month) use of organic nitrate vasodilators or riociguat 2. Current/ongoing (within past month) use of ritonavir (HIV-protease inhibitor) 3. Current/ongoing (within past month) use of erythromycin, ketoconazole, or itraconazole 4. Current/ongoing (within past month) use of cimetidine 5. Current resting hypotension (BP \< 90/50 mm Hg) 6. Current severe renal insufficiency 7. Current hepatic cirrhosis 8. Current cardiac failure or coronary artery disease causing unstable angina 9. Retinitis pigmentosa 10. Known hypersensitivity or allergy to sildenafil of any of its components 11. History of melanoma or suspicious skin lesions for melanoma on skin examination 2. Daily therapy with a PDE5 inhibitor within the month prior to consent 3. History of penetrating TBI 4. History of disabling neurological or psychiatric disorder not related to TBI 5. Active substance abuse or dependence during the past 6 months 6. Estimated preinjury intellectual level ≤70 (based on educational and vocational history) 7. Inability to understand written and spoken English, in the opinion of the investigator 8. Current inclusion in another interventional trial 9. Subjects with metal implants that would interfere with the MR imaging procedures 10. History of priapism 11. Pregnant or breast-feeding women 12. Actively suicidal (based on clinician assessment OR if patient endorses item 9 on Patient Health Questionnaire 9 (PHQ-9) and endorses suicidal ideation on Columbia Suicide Severity Rating Scale(CSSRS) 13. Hypertension requiring treatment with more than two antihypertensive drugs 14. Hyperlipidemia requiring treatment with more than one lipid lowering drug 15. Diabetes mellitus requiring medical treatment with insulin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic traumatic brain injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.